Table 1.
Evaluation of novel drug candidates for targeted therapy using a non-small cell lung cancer spheroid model.
| Molecular target | Inhibitor | Spheroid model | Anticancer effect | Reference |
|---|---|---|---|---|
| MCL-1 | S63845 | Ex vivo mice pulmospheres | Genetic deletion impedes pulmosphere growth | (90) |
| Glut1 and PDH | Bay-876 and CPI-613 | H1299 and H1792 homotypic spheroids | Inhibition of spheroid growth | (91) |
| GSK-3 | CHIR-99021 | Heterotypic spheroids of lung cancer cell lines (NCI-H460, A549, and SK-MES-1) and stromal cells (WI38 and HUVEC) | Enhances the efficacy of anticancer drugs in vitro and in vivo | (65) |
| STAT3 | Biscoumarin OT52 | Homotypic A549, H460, H1650 spheroids | Inhibition of spheroid formation | (92) |
| ATP synthase | Oligomycin | H446 spheroids | Inhibition of spheroid formation | (93) |
| miR-149-5p/MyD88 | Ursolic acid | A549 paclitaxel resistant spheroids | Reduced stemness and paclitaxel resistance | (45) |
| TRAIL | Adenovirus ZD55-TRAIL | A549 spheroids | Induction of A549 cell apoptosis in spheroids | (94) |
| GO-203 | MUC1-C | A549 spheroids | Inhibition of A549 spheroid formation | (95) |
| Wnt/β-catenin | Trifluoperazine | Patient-derived cell line spheroids | Inhibition of spheroid formation | (96) |